Impact of Treatment Selection and Real-World Outcomes in Advanced RCC

This is a video synopsis/summary of a Post Conference Perspectives featuring Brian Rini, MD, and Hans Hammers, MD, PhD.

Rini discusses an abstract presented at the 2023 International Kidney Cancer Symposium by examining real-world outcomes with axitinib (Inlyta) plus pembrolizumab in kidney cancer patients. Using the Flatiron database of over 800 US sites, the analysis aimed to compare efficacy to clinical trial populations.

Rini notes such real-world analyses are valuable to confirm if trial findings translate to broader patient groups encountered in clinical practice, who are often less selected than trial participants. Here the axitinib/pembrolizumab results recapitulated those seen in the KEYNOTE-426 trial in terms of response rates and progression-free survival.

While these real-world analyses likely won’t change standard treatment decisions, Rini states it is reassuring that efficacy did not substantially drop off compared to trial populations. So in this case, the data serves to reinforce the benefit of axitinib/pembrolizumab seen in kidney cancer.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.